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Mouse mammary tumor is a common form of cancer used 
for experimental purposes. It is relatively resistant to 
chemotherapy. This investigation is designed to test the 
effect of heparin, a naturally occurring anticoagulant, on 
tumor growth using a genetically uniform laboratory animal. 
The c3H/HeJ Mouse 
Dr. Clarence C. Little was among the first to recog-
nize the usefulness of genetic uniformity in reducing the 
variables associated with experimental work (1). He pointed • 
out that genetically similar populations allow investigators 
to check their own observations and allow other researchers 
to verify the results (1) . Use of the c3H strain of mouse in 
the present project eliminates histocompatibility problems . 
The c3HjHeJ mouse, which is agouti in color (2) 
is a strain of the c3H mouse de veloped by careful inbreeding . 
The J indicates that it is a subline of c
3
HjSt, a strain 
developed by Strong (2,3). The c
3
H mouse was, in turn, 
developed from the C family and was initially introduced 
around the year of 1918 (4-12). 
Between the y e ars of 1918 and 1920 (2,3,4-13), Strong 
1 
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crossed a female Bagg albino mouse with a DAB* male to pro-
duce the inbred strain c
3
H which was developed separately from 
other strains (2, 4-12). In 1930, Strong gave the c
3
H mouse 
to Andervant. About 1938 -1941, Andervant passed the c3HjHeJ 
mouse at F35 to Heston (the F35 refers to the inbreeding of 
the 35th generation of brothers and sisters). In 1947-1948 
Heston gave the F48, which is the 48th breeding of brothers 
and sisters, to Jackson Laboratory and in 1980 this labora-
tory purchased the Fl50 generation from Jackson Laboratory 
for this research. 
The c
3
H strain has more than 10 major sublines (14). 
Most of these sublines have good reproductive capacity (14) 
and exhibit a very high incidence of spontaneous mouse 
mammary tumor (2,3,13-16). 
Strong and Heston have indicated that the incidence 
of the spontaneous developing mouse mammary tumor in the 
c3HjHeJ mouse is highest in the breeding female (65%), lower 
in the virgin female (28%) and lowest in the male (2 - 3,17). 
The c3HjHeJ subline exhibits a uniformity in a variety 
of characteristics useful for experimental biology (1,2,13). 
Certain characteristics, such as coat color and rd (retinal 
degeneration gene), are highly uniform (2,4-11). Minor fac-
tors, such as the life span, susceptibility to constitutional 
disease, and other physiological characteristics are not 
* Little's mice were used in color experiments and 
represent one of the oldest inbred strain (since 1907). 
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absolutely uniform because their expression is a function 
of both heredity and environment (2,13,18) . The uniform 
genetic c haracteristics of the c
3
H mo us e are of gr eat im-
portance in certain aspects of cancer. These findings 
make the unfostered sublines appropriate models for research 
into mammary tumor biology (13, 18-21). 
The c3HjHeJ subline exhibits a poor immune r esponse 
to endotoxic lipopolysaccharide ( 14); this is thought to be 
due to a B lymphocyte de f i c it . One exp lanation fo r this ab-
normality of the c3HjHeJ immune system would be an a ltered 
he matopoeitic system s ince both low r e d and whit e cel ls 
counts are observed in the live animal (4-ll). 
An understanding of mammary tumor morphology requires 
study' of normal and abnorma l mammary tissue. In the fol l ow-
i ng section, these topi cs will b e discussed: (i) the no rmal 
mouse mammary tissue, including gross morphology a nd micro-
scopic anatomy, and (ii) tumorous mouse mammary tissue, in-
eluding pathogenesis and facto r s influe n c ing tumorogenesis . 
No rmal Mouse Mammary Tissue 
' 
A c3HjHeJ mouse has five pairs of mammary g l a nds , 
t hree thoracic and two inguino-abdominal (22). Dissect ion of 
these g l a nds s hows that t h e healthy tissue is opaque, whit e 
in co l o r and pulpy in texture ( 2, 2:3 , · 24). 
Histologically, normal mouse mammary tissu e undergoes 
various c hanges durin g pube rty, pregnancy, lactation, a nd 
involution (20,25-28). The inactive mammary gland (Figure 1) 
Figure 1. C3HjHeJ mouse inactive mammary tissue (10 X). Note the low ratio 
of glandular tissue (elements) to adipose tissue. 
~ 
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is hypoplastic with very few glandular elements (25). Preg-
nancy (Figure 2) induces remarkable growth of tubules and 
secretory alveoli (29). The alveoli are empty _of secretio ns 
early in pregnancy (29, 30). 
The most remarkable change occurs durin g lactation 
(Figure 3), when the alveoli increase in size . At this 
time, most of the alveolar lumens contain large volumes of 
lipid and protein secretions (31). This situation continues 
until the involutional stage (Figure 4) . At th a t time, con-
traction of the glandular tissue takes place and t he alveoli 
become smaller although they remain irregular (25,26). 
Mous e Mammary Tumor 
On April 24, 1946, a spontaneous ma mma r y a de nocarcin-
oma was detected in a nine-month-old female mouse of the 
s train c3H. The tumor was c h a r acterized and transplanted 
(32) . Since that time, ma mmary adenocarcinoma tissue has 
been transplanted s u ccessfully by subcutaneous, intramus-
cular, intraocul ar, intrahepatic and intraperitoneal inocu-
lation . 
Mouse ma mma r y tumor i s of two histo l ogical types: 
o ne consistin g of s mall, uniform acin i s upported by minimal 
str o ma; the other, a so lid mass of tumor cells arranged i n 
nodul es surrounded by co nnective tissue (23,24,33). The 
latter ( Fi gur e 5) h as been ob served more of t e n in the c
3
H 
mouse (23,24 .,34) . 
Altho ugh t h e transplantability characteristic of 
Figure 2 . C3HjHeJ mouse p r egnant mammary tissue (10 X) . Note the increase 
in relative numbers of mammary acini to adipose tissue . Also 
observable is the presence of lipid and protein secretions in ducts . 
0') 
Figure 3 . C3HjHeJ mouse lactating man~ary tissue (10 X) . A striking increase 
in glandular elements with relative reduction in connective/adipose 
tissue can be observed. 
....:] 
Figure 4 . C3H/HeJ mouse involuting mammary tissue (10 X) . Note a reduction 
of glandular elements; appearance is similar to the inactiv e state . 
(X) 
Figure 5 . C3HjHeJ mouse spontaneous mammary tissue (10 X) . A solid mass of 
glandular like tissue with scant connective tissue is shown here . 
CD 
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the mouse mammary tumor tissue is by far the most important 
indicator for its malignant nature (35), other characteris-
tics such as a naplasia and rapid growth with demise (death) 
of the animal are also strong evidence for its malignant 
nature (15, 18). 
Mouse mammary tumor virus has been known to be 
oncogenic since 1918. An RNA oncogenic virus, mouse mamma ry 
tumor virus (MMTV), is transmitted from an infected mother 
to the offspring by nursing (13, 15, 16). 
The mouse mammary tumor virus can be identified in 
the milk (15, 16). A spontaneous mouse mammary tumor will 
develop in a genetically susceptible animal unde r the in-
fluence of this virus and probably other e nviornmental fac-
tors ·c 15). Several factors influence tumorogenesis ( 36) 
includin g: 
(i) Virus: Other viruses in addition to mouse 
mammary tumor virus are known to cause mouse 
mammary tumor ( 15, 36, 37) . 
(ii) Genotype: The susceptibility of mice to 
develop spontaneous mo use mammary tumor is 
depende nt o n here dity (15 , 16). In some r e -
sistant strains such as C57BL, I, 020 and 
C57BL/l0, mouse mammary tumor virus will fail 
to develop a high mammary cancer incidence (15). 
(iii) Hormonal Environment: Virus -induced mammary 
tumors are essentially hormone-independent 
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(16); they can grow not only in normal fe-
males but also in castrated females or in 
males (16). However, in susceptible (virus-
carrying) strains of mice, such as the c
3
HjHeJ 
mouse, hormonal stimulation results in much 
higher incidence of mouse mammary adenocarcinoma 
(16). This hormonal factor has been supported 
by many experiments showing that ovarian ex-
tracts, estrogen or estrogen-progestogen 
combinations do, in fact, stimulate oncogenesis 
(38); others such as glucocorticoids, dex-
amethasone, prolactin, and insulin also seem 
to play some role (39~45) · . 
Tumor Transplantation 
Tumor transplantation is a technique where by a viable 
tumor can be transplanted from a donor animal to a syngeneic 
host. The value of this technique resides in the fact that 
tumor viability can be maintained continuously as cells are 
passaged from one animal to another. This technique is of 
great value in cancer and/or immunological research (46). 
The history of tumor transplantation goes back more 
than a century when many investigators thought that the trans-
plantable tumors might be better tools for cancer andjor im-
munological r e search than spontaneous or induced tumors. In 
1876, M.A. Novinsky (1841-1914), known as the father of 
tumor transplantation, successfully transplanted, possibly 
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for the first time, a spontaneous malignant tumor. He used 
a dog because at that time small laboratory animals were not 
widely used (47). 
Novinsky drew several conclusions: first, he noted 
that it was possible to perform implantation of a tumor; 
second, that inoculation success depended on several fac-
tors: (i) size of the initial incision of the skin, (ii) 
the size of the tumor inoculum, and (iii) the quantity of 
viable cells present in the transplant. He also suggested 
that tumor cells should be considered as infecting agents 
to healthy tissue, and that species identity between the 
donor and the host should be considered during inoculation 
( 47). 
The credit for successful tumor transplantation in 
laboratory animals has been misguidedly awarded t o Hanau , 
who in November 28, 1888 successfully inoculated two rats 
with an epidermoid rat carcinoma. Hanau himse lf refers to 
Novinsky's work on tumor transplantation in dogs (47,48). 
During the period of 1889-1952, Kanematsu Su giura 
with three other authors, as well as four independent investi-
gators, reported that rat and mouse tumors as well as vener eal 
sarcoma in the dog could be successfully transplanted (47). 
At the present time, there are more than 100 known 
transplantable tumors of the mouse, rat, hamster, guinea pig, 
rabbit, dog, a nd c hicken. 
Even minor factors (di scussed later) play an important 
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role in the success of tumor transplantation. Successful 
transplantation of a solid tumor requires the following in-
struments: stainless steel dissecting scissors, forceps 
with medium point, curved dissecting forceps, dissecting 
knife and trocars (46). The trocar is a special stainless 
steel 13-gauge instrument made especially for tumor trans-
plantation . The wide bore of the trocar is well known to 
cause less damage to the tumor cells. 
In solid tumor transplantation, it has been recom-
mended that the non-necrotic, nonhemorrhagic tumor mass be 
cut into small cubes prior to transplantation since the 
response in the host and tumor survival will depend on the 
size of the tumor mass (46). 
Tumor transplant growth is facilitated if trans-
planted into a histocompatible host or an immunosuppresse d 
host or a n a nimal such as the nude mouse. Otherwise, the 
normal immune system, in particul ar T lymphocytes, may re-
j ect it (46, 47) . 
Because of the ease of transplantation, the most 
suitable site is into axillary subcutaneous tissue. It 
has been noted that tumor take and growth are best in young, 
healthy, vigorous mice and r ats, r egardless of sex although 
sexes should be separated to prevent pregnancy (46). 
Successful mouse mammary tumor impl e mentation can be 
detected at the implementation site within a week (46, 47) . 
In the ma mmary adenocarcinoma transplant, rapid growth is 
generally ob ser ved , although this i s dependent o n several 
14 
factors such as inoculation size and site. Animal death 
occurs within weeks (46). 
Other factors can contribute to the failure of trans-
planted tumor cells to establish themselves. The se include: 
(i) inoculation of stationary or receding tumors, (ii) inocu-
lation of stored frozen tumors, (iii) spontaneous regression 
of transplantable tumors, and (iv) resistance to inoculation 
(46,47). 
Dvorak Model 
In 1979, Dvorak et al., postulated that solid tumors 
have the ability to stimulate the formation of a protective 
fibrin cocoon around the tumor (49). Dvorak suggested that 
this "fibrin cocoon might enable the tumor cells to develop 
without challenge from the host's immune surveillance system 
or provide some other survival advantages (49-54). 
Prior to cocoon formation, tumor cells release a 
vascular permeability factor (VPF) at an early stage after 
transplantation. This factor increases vascular permeability 
locally in the region of the tumor, allowing blood constitu-
ents, including fibrinogen, to escape into the tissue border-
ing the tumor. The VPF is not histamine mediated (49). 
In addition to the release of the VPF factor , tumor 
cells release a procoagulation factor (PCF) which in turn 
triggers the blood clotting cascade leading to fibrin forma-
tion in the form of a cocoon . This has been observed to 
occur within hours aft e r transplant (49). 
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In order to allow for future tumor growth, Dvorak 
postulated production of a third factor called plasminogen 
activator factor (PAF). PAF activates plasmin to stimulate 
fibrinolysis and as the tumor grows, the cocoon is then 
able to be reshaped. 
A migration inhibitory factor (MIF), which has the 
capacity to inhibit migration of macrophages to the tumor 
zone, is postulated by Dvorak as an additional (fourth) fac-
tor promoting tumor growth (49). 
The central core of the Dvorak hypothesis is the 
fibrin cocoon. He has suggested that the cocoon is advan-
tageous for tumor growth since it may protect neoplastic 
cells from the host immune surveillance system. He also 
noted that the fibrin cocoon is apparently associated with 
the development of new blood vessels that penetrate the 
tumor (49). The presence of the fibrin cocoon has been 
confirmed by immunofluorescence as well as by electron 
microscopy. 
Special Project 
Other workers have noted a relationship between 
tumor growth and coagulation. In 1958, Wood demonstrated 
that tumor cells have to become engulfed in a fibrin 
clot as a prerequisite for metastasis (53). This was fol-
lowed in 1960 by the work of Hiramoto et al., who demon-
strated the presence of e xtravascular fibrin deposits within 
tumors (54). In 1971 it became clear (Folkman) that a tumor 
fibrin matrix supporting a capillary network was essential 
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for tumor survival (55). Lastly, several investigators 
between the years of 1973-1981 (Elias et al . ; Brown; 
Zacharski et al.; Poggi et al. ), have shown that anti-
coagulants will protect the host against metastasis 
(56-60). 
The present research project was designed to examin e 
the effect of a naturally occurring anticoagul a nt (heparin) 
on tumor growth in an experimental animal . The hypothesis 
was to test the relationship between heparin and Dvorak's 
hypothesis using transplanted mammary tumors and the c3HjHeJ 
female mouse, ' known for its high incidence of spontaneous 
mammary tumor. As a solid tumor, mammay tumor tissue is 
ideal for such investigation since solid tumors can be re-
trieved and weighed easily. 
Heparin, since its discovery in 1916, has been used 
world wide clinically for its anticoagulation properties 
(61-80). The mechanism of action involves its highly 
charged acidic properties. Heparin action sites in the 
coagulation cascade are indicated in Figure 6 (66, 79). Al-
though it has several sites of action, its dominant effect 
is the inhibition of thrombin formation. 
Brambel proposed that heparin, with its cofactor 
antithrombin III, inactivates factor V by forming a "heparin 
cofactor-factor V heparin complex" (80). This results in 
a deficiency of the prothrombin activator complex which is 
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Figure 6 . Intrinsic clotting sequence. (Known sites of 
heparin action are indicated with an asterisk.) 
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Factor V plus phospholipids and calcium . The net result of 
this inhibition is a decrease in thrombin production (66, 
69, 79). The "heparin cofactor-factor V heparin complex" 
undoubtedly occurs because heparin is a strongly charged 
(negative) molecule (69). 
Another observation has been made by Soulier and 
Lewis, who noted that the presence of a heparin cofactor, 
a plasma alpha-globulin called antithrombin III is essential 
(79,81,82) for its antithrombotic activity. 
In the body, heparin is stored naturally in mast 
cells bound to histamine and 10-24 units %, (0.1 - 0 .24 mg/ 
100 ml) can be found circulating in blood plasma, where it 
presumably acts as a "natural" anticoagulant ( man, horse) 
( 69). In addition to its anticoagulant activity, heparin 
has some "antiinflammatory" properties. Dragstedt, in 1942 , 
observed that histamine reacts with heparin to form a non-
reactive (histamine-heparinate) complex, thereby inhibiting 
the release of histamine during an antigen-antibody reac-
tion (83). This antiinflammatory action is not related to 
anticoagulant activity (84) . 
Heparin is also known to have some antilipemic and 
anticomplementary activity (6'7, 84) . 
MATERIALS AND METHODS 
Tumor Transplantation 
To obtain material for implantation, a female donor 
C3HjHeJ mouse with a spontaneous mammary tumor (Figure 7) 
was sacrificed using diethyl ether. The dorsal surface of 
the dead animal was swabbed with 70% ethanol, an incision 
made, skin retracted and pinned back, and the tumor care-
fully dissected from the surrounding tissue. When separated 
from surrounding tissue, the tumor appeared as an opaque, 
yellowish-white mass . After several washings using sterile 
Ringer's solution (46), the tumor was dissected into c ubes 
measuring approximately 2 x 2 x 2 mm (see Fi gure 8) with an 
average weight of 0 . 0179 g (obse rved range= 0 . 0115 
0.0244 g) . 
Fifty-four (27 control), c3HjHeJ females weighing 
20-26 g were used as the host animals (85,8G) . Tumor im-
plants o~ the above dimension and consisting of approximately 
6.3 x 108 cells were used . Animals were exposed to diethyl 
e ther for approximately 50 seconds until moto r coordination 
was lost . With the animal prone, a 3 mm incis ion was made 
on the lowe r back after bathin g the area with 70% ethanol 
(Figure 9). A 13-gauge needle, containing tumor tissue, was 
introduced subcutaneously into the tissue via the s k i n incision 
19 
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and directed toward the implantation site midway between the 
left shoulder and left hip in the axillary line (Figure 10) . 
Tumor implantation was completed by introducing a plunger 
into the barrel of the needle. A clockwise followed by a 
counter-clockwise rotation of the plunger insured complete 
evacuation of the tumor. The trocar and its plunger were 
carefully removed. No sutures were required to repair the 
skin incision. Tumor samples were randomly distributed by 
weight within the test groups. 
Drug Treatment 
Twenty-four hours prior to tumor transplantation , 
the 54 experimental animals were divided randomly into two 
groups: 27 as control and 27 which received intraperito-
neally 4 mgjkg heparin sodium (128 Ufmg) at that time. This 
is twice the normal anticoagulation dose. The experimental 
group continued to receive heparin sodium (4 mgjkg) every 
12 hours . 
Whole Blood Clotting Time Measurement 
Using a tapered glass pipette (approximately 10 em 
in length), approximately 2.0 ml of blood were drawn from 
the periorbital venous plexus of the eye . This sample was 
then placed in a well on a thin glass plate and housed in 
0 a water bath at 37 C. The sample was quickly held in a 
perpendicular position every 30 seconds until a firm clot 
had formed (87). 




Tumor Dissection and Photography 
The experimental and control animals were sacrificed, 
using diethyl ether according to the Experimentation Schedule 
shown in Table I. 
After washing the dorsal skin with 70% ethanol, a 
midline dorsal incision was made from the sacral area up to 
the base of the neck (Figure 11). The skin was retracted 
slowly while it and the tumor were carefully dissected from 
the underlying back musculature (Figure 12). Both sides 
of the dorsum were exposed equally for comparison regarding 
local edema, vascular congestion and tumor appearance 
(Figure 13). Photographs were taken prior to the removal 
of the tumor. The tumor was then carefully dissected from 
the supporting skin tissue (Figure 14) noting its adherence 
-4 or non-adherence, carefully weighed to the nearest 10 g 
using a Sartorius balance (type 2463, Fab. #161122) (Figure 
15), and preserved in a 40% formaldehyde solution. 
Histology 
In the histology group, the tumor was removed with 
the overlying skin for histological evaluation. All speci-
mens were labeled with time of sacrifice, date, and origin 
of specimen (control, experimental, histological group). 
The specimens were the n processed by embedding them in 
paraffin. After sectioning (7 microns thick), slides were 
stained with hematoxylin/ e osin for microscopic study. The 
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Figure 13. Bilateral skin reflection for comparison. Note the increase 






a. After sectioning, a specimen was positioned 
on a slide and placed on a drying plate at 
37°C for 24 hours, then 
b. Washed in 70% ethanol, then 
c. Placed in xylol 2 min to remove excess paraffin, 
then 
d. Tranferred successively to 100%, 95%, 70%, 50%, 
and 30% ethanol, 1 min each, then 
e . Stained in Harris' hematoxylin (diluted 1:9 with 
distilled water) for at least 15 min, then 
f. Placed successively in 30% and 50% ethanol for 
1 min each, then 
g. Destained in 70% acid alcohol until.sections 
appear light red on gross inspection , then 
h. Washed momentarily in 70% ethanol to remove ex-
cess acid and placed in 70% alkaline alcohol 
until sections became bluish in color, t hen 
i. Counterstained in 0.5% eosin in 95% ethanol 
for 1 min, then 
j. Washed in 95% ethanol only until the excess 
eosin was removed and the sections appeared 
purp l e in color, then 
k . Placed in absolute ethanol for not over 1 min 
(prolonge d exposure to e thanol will remove 
all the eosin), then 
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1 . Cleared in xylol (1 min o r longe r) and mounted 
(thin medium no . 1 coverglass), and lastly 
m. When sufficiently harde ned, cleaned and 
labe led. 
Animal Weight 
All animals were weighed to the nearest g prior to 
the implantation and at the time of sacrifice. 
Stati s tical Evaluation 
In many investigations the researche r is primarily 
interested in discovering and evaluating diffe ren ces between 
effects rather than documenting the effects themselves . In 
the comparison of the group means, the term treatme nt i s used 
to refer to the basis on which the two groups were dif-
f erentiate d . The goal of this statistical analysis (analysis 
of variance) was to es tablish whether o r not a n y difference 
between the two tre atments was significant (p < 0 . 05) . 
A definitive evaluation of the dat a was then conducted 
utilizing multi-variate analysis. 
RESULTS 
Statistical Comparisons 
Tables I I and III li s t the raw data obtained whi le 
Table IV carries the mean data a nd corresponding standard 
error of the me an. 
A very highly significant diffe rence in whole blood 
clotting time was seen between the control and the experi-
mental group (Table V) . Th e average clotting time in the 
experimenta l gr o up was prolonged in comparison to the aver-
age c l ot ting time in t h e control group (£ = < 0 . 001) . This 
i llustrates the well known a nt i coagulan t action of heparin, 
• 
t he only drug used in this study . 
A ve r y hi ghly sign ificant difference (£ = < 0 . 001) in 
tumor we i gh t was also detected between t he two groups (Table 
VI) . This i s probably not due to d iffer e nces in i noculum 
size, s ince inoculum s i ze was randomly distributed between 
the experimental a nd con trol groups. There was no significant 
difference in body weight changes between t he control and 
th e experime nt a l gr o ups (Table VII). 
In the control gr o up there was a t r e nd toward in-
c r eas in g tumor s i ze with time but t hi s was no t statistical l y 
signi fican t (Table VIII ) . In t he experime ntal gr oup tumor 




Raw Data for Untreated Group 
Time, Tumor Weight, Clotting Time, Body Weight 
No. hrs mg min Change, g 
1 6 06.5 2.3 - 0 . 2 
2 6 10 . 7 1.1 - 0.2 
3 6 14 . 1 1.2 00 . 3 
4 12 14.6 1.5 00 . 2 
5 12 09.2 2 . 7 00 . 0 
6 12 06.8 2.1 00 . 0 
7 24 06.2 1.3 00 . 0 
8 24 17 . 8 1.0 00.1 
9 24 14.3 1.5 00.0 
10 48 04 . 4 1.9 00.0 
11 48 05.5 2.0 00 . 2 
12 48 09 . 7 1.8 00 . 0 
13 48 09 . 0 1.6 00.2 
14 48 10.3 1.7 00 . 0 
15 48 08 . 2 2.0 00 . 0 
16 96 09.4 1.5 00 . 2 
17 96 20 . 7 2 . 0 00 . 0 
18 96 11 . 5 1.8 -0.2 
19 192 08 . 1 1.2 00 . 3 
20 192 09 . 6 2 . 1 00.2 
21 192 09 . 8 1.2 00 . 4 
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Table III 
Raw Data f or Treated Gr oup 
Time, Tumor Weight, Clotting Time, Body Weight, 
No . hrs mg min Change , g 
22 6 07.5 4 .4 00.0 
23 6 06 . 3 1.8 00 . 0 
24 6 05.2 4 .4 00 . 0 
25 12 02.8 17. 6 00 . 0 
26 12 05 . 1 2. 6 00 . 0 
27 12 01.7 8.0 00 . 0 
28 24 05.2 2. 9 - 0 . 2 
29 24 05.8 4.3 - 0 . 2 
30 24 02 . 7 3.4 00 . 3 
31 48 02.1 3 . 3 00.4 
32 48 06.3 3 . 6 00 . 3 
33 . 48 05 . 3 2 . 7 00 . 4 
34 48 06 . 0 3 . 2 -2 . 0 
35 48 05 . 3 3.0 - 0.4 
36 48 04.8 2 . 9 00 . 2 
37 96 04.6 3 . 5 00 . 3 
38 96 04 . 9 4.2 -0. 4 
39 96 05.8 5 . 2 - 0 . 4 
40 192 03 . 7 3.1 00 . 4 
41 192 05 . 7 5.1 00 . 5 
42 192 06 . 3 1.1 00 . 4 
Table IV 
Mean Values + 1 Standard Error of the Mean 
Time in Hours 
Term 6 12 24 48 96 192 
Tumor T 6.330 + 0.664 3. 200 + 1.002 4.560 + 0.949 4.960 + 0.614 5.100 + 0.255 5.230 + 0.786 - - -
Weight, g u 10.430 + 2.170 10.190 + 2.186 12.760 + 3.435 7.850 + 0.971 13.860 + 2.454 9 . 160 + 0.537 
Clotting T 3.5 + 0.9 9.4 + l. 7 3.5 + 0.4 3.1 + 0.1 4.3 + 0.5 3.1 + 1.2 - - -
Time, min u 1.5 + 0.4 2.1 + 0.3 1.3 ±. 0.1 1.8 + 0.1 1.8 + 0.1 1.5 + 0.2 -
Weight T 0.0 + 0.0 0.0 + 0.0 -0 . 3 + 0.0 -1.8 + 0.4 -1.7 + 0.2 4.3 + 0.0 w - .....:) 
Change, g u -0.3 + 0 . 2 0. 7 + 0.1 0.3 + 0 . 0 0.7 + 0.0 0.0 + 0.1 3.0 + 0.1 
T = treated group 
U = untreated group 































~ = Observed level of significance 





























s = 9 . 178 
F obs . 
33.30 
1.19 
£ = Observed level of significance 
F . 0.05 cr1t. 
4 .12 























6 . 401 
df = Degrees of freedom 
Table VII 
Analysis of Variance Test Regarding 
Body Weight Change 
Mean Square 
0 . 086 
0 .174 
2 




.E. = Observed level of significance 














Analysis of Variance Within the Untreated 









F . 0.05 
cr1t . 




>0 . 8 
>0 . 6 
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(incr ease in tumor mass). This again, however, was not a 
significant difference (Table IX). Also clotting times 
and body weigh~ changes within each group remained statis-
tically u nchanged . 
The results were subjected to multiple-variate 
a nalysis (ANOVA). From Table X it is obvious that treat-
ment has affected tumor growth significantly (£ = < 0.0001). 
Time has no signi ficant effect on tumor weight . There is 
no significant interaction between treatment and time with 
reference to tumor weight . Therefore, it is apparent that 
tumor weight differences are attributable to treatment and 
not to time. 
Table XI demonstrates clotting times are significantly 
affected by treatment. The treatment group has much longer 
clotting times than the control group . Duration of t r eat-
ment has an effect atE= 0 . 06 but has no effect atE= 0.05 . 
In other words, at E = 0.05 (the traditional probability 
l evel for biological research) there i s no significant inter-
action between treatment and duration of treatment with ref-
erence to their effect on clotting time; a large number of 
test subjects would probably produce significant interaction. 
Table XII demonstrates no significant difference in 
body weight changes . Neither treatment nor time has any sig-
nificant effect on changes in body weight of the animals . It 
is probable that if this study has been contained for a longer 
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>0 . 4 
>1.0 
Table X 
ANOVA Multivariate Analysis of the Interaction between Tumor Weight as the Dependent Variable 
with Treatment and Time as the Independent Variables 
Source of Sum of 
Variation Squares df Mean Square F obs . F . 0.05 cr1t. E. 
Main effects 360.289 6 60.238 6.827 2 . 42 <0 . 000 
Treatment 305.640 1 305.640 34.751 4.17 <0.000 
Time 54.649 5 10.930 1.243 2.53 0.314 
Two-way 
interaction 57.364 5 11.473 1 . 304 2 . 53 0.288 
Explained 417.653 11 37.968 4.317 2 .10 0 . 001 
Residual 263.855 30 8.795 




ANOVA Multivariate Analysis of the Interaction bet ween Cl otting Time as the Dependent Variable 
with Trea t ment and Time as the Independent Variables 
Source of Sum of 




Main effects 126 . 596 6 21.099 4 . 743 2.42 0.002 
Treatment 71.501 1 71.501 16 . 073 4.17 0.000 
Time 55.095 5 11.091 2 . 477 2.53 0.054 
Two way 
interaction 40.548 5 8.110 1 . 823 2 . 53 0. 138 
Explained 167.144 11 15 .195 3 . 416 2.10 0.004 
Residual 133.455 30 4.449 




ANOVA Multivariate Analysis of the Interaction between Body Weight Change as the Dependent 
Variable, Treatment, and Time as the Independent Variables 
Source of Sum of 
Variation Squares df Mean Square F obs. F . 0 . 05 cr1t. E. 
Main effects 0.955 6 0.159 0.907 2.42 0.503 
Treatment 0.086 1 0.086 0.490 4.17 0 . 480 




interaction 0 . 185 5 0.037 0 . 211 2.53 0 . 955 
Explained 1.140 11 0.104 0 . 591 2.10 0.821 
Residual 5 . 262 30 0.175 
Total 6.401 41 0.156 
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in body weights. 
Macroscopic Comparison s 
On gross observation, there was no difference 
between the control a nd the exper imental group with reference 
to color, texture and general appearance of the implanted 
tumor at sacrifice. However, surrounding vascular conges-
tion as evidenced by local vasodilation and local edema ap-
peared to be more pronounced in the control group (see 
Figures 16 - 19). Also an overlying skin attachment ap-
peared to be more freq uent in the con trol group. 
Table XIII summarizes the observed incidence of 
vasodilation and local edema--parameters which did not 
lend -the mselves to precise measurement. As the tumors were 
b e ing removed, both sides of the skin were exposed . Each 
animal during dissection was graded a plus or a minus ac-
cording to t he degree of vasodilation . During tumor dis-
section, local edema was also graded in a subjective man-
ner. In addition,no a reas of hemorrhage were seen . 
Microscopic Comparisons 
Tumor sections from the two groups were evaluated 
microscopically for the numbe r of viable cells . The r e ap-
peare d to be a g r eater number of viable cells in the control 
group (Figures 20, 22 , 24, 26, 28, 30) . In the experime ntal 
group, viable cells were limited to the zonal area at the 
surface of the t umor (see Figures 21, 23, 25, 27, 29, 31). 
Figure 16 . Demonstrating vasodilation in control animals (Day +2). Note the 




Figure 17. De monstrating vasodilation in experimental animal (Day +2) . In the 




Figure 18 . Demonstrating vasodilation in control animals (Day +4). Obvious con-
gestion of overlying skin vessels is observed . 
CJl 
0 
Figure 19. Demonstrating reduced vasodilation in experimental animals (Day +4). 






Quantal Incidence of Rated Factors 
Time in Hours 
6 12 24 48 96 192 
Vasodilation T 0/3 0/3 1/3 0/6 0/3 3/3 
u 0/3 1/3 2/3 3/6 3/3 3/3 
Local Edema T 0/3 0/3 ·1/3 2/6 2/3 3/3 
u 0/3 1/3 3/3 3/6 3/3 3/3 
Figure 20 . Mouse mammary tumor in control group at 6 hours (25 X). At 6 
hours necrotic and viable tumor cells are observed . 
(J1 
w 
Figure 21. Mouse mammary tumor in experimental group at 6 hours (25 X) . Much 




Figure 22. Mouse mammary tumor in control group at 12 hours (25 X). In contrast 
to Figure 20, an area of central necrosis is observed. Tumor is more 
cellular and necrosis less evident. 
(}1 
CJl 
Figure 23. Mouse mammary tumor in experimental group at 12 hours (25 X). Central 
necrosis with viable tumor cells seen only at the periphery. Note also that 
PMNs and macrophages appear at the tumor's periphery. 
(J1 
(j') 
Figure 24. Mouse mammary tumor in control group at 24 hours (25 X). Again note a 
mass of neoplastic cells with fewer inflammatory elements and a lack 
of a central necrotic region. 
(}1 
~ 
Figure 25. Mouse mammary tumor in experimental group at 24 hours (25 X). A cen-
tral necrotic area can be observed. 
CJ1 
00 
Figure 26. Mouse mammary tumor in control group at 48 hours (25 X) . This section 
is similar in appearance to Figure 20 and Figure 22 . Tumor lacks a 
central necrotic area. 
(Jl 
\!) 
Figure 27 . Mouse mammary tumor in experimental group at 48 hours (25 X). A large 
area of necrosis with very few viable . tumor cells can be observed. 
(j') 
0 
Figure 28. Mouse mammary tumor in control at 96 hours (40 X). At higher magni-
fication, nests of growing tumor cells can be observed . 
0) 
}-J. 
Figure 29. Mouse mammary tumor in experimental group at 96 hours (25 X) . Viable 
tumor cells are observed only at the periphery of the tumor . 
(j) 
N 
Figure 30. Mouse mammary tumor in control group at 192 hours (40 X). Solid 
tumor lobules separated by connective tissue with neo-vasculature. 
0') 
0.:: 
Figure 31. Mouse mammary tumor in experimental group at 192 hours (40 X). A large 
area of necrosis with relatively low numbers of tumor cells located a long 




Definite necrosis was seen in most of the histologic sections 
prepared from experimental animals. However, in a few slides 
viable cells were seen centrally and these were thought 
to be the result of the sectioning process (see Figures 23, 
31). 
Leukocyte infiltration (polymorphonuclears, micro-
phage, lymphocytes) was observed, and a great deal of intra-
group variability was seen (see Figures 20-31). 
DISCUSSION 
This experiment was designed to demonstrate any 
effects that heparin might have on the growth of implanted 
mammary tumors in a susceptible, genetically uniform breed 
of mice. 
It is clear from the data collected here that 
heparin treatment affects tumor growth as early as 6 hours 
after tumor implantation. This inhibitory effect became 
progressively more apparent until the time of sacrifice. 
This favorable r esponse is probably related to heparin's 
antithrombin activity. The premise could be substantiated 
by designing a study in which heparin is replaced by an 
a nti coagulant agent with a differe nt mechanism of action 
such as coumarin. Coumarin primarily affects the synthesis 
of Vitamin K-dependent clotting factors (serum beta globu-
1 ins). 
The dose of heparin use d in this experiment, twice 
the normal dose, clearly prolonged the clotting time, a 
necessary consequence of its inhibitory action o n thrombin 
formation. Since the presence of thrombin favo rs the forma-
tion of a stabl e "fibrin cocoon" f o r the tumor (49), heparin 
theoretically should be able to preve nt the formation of 
this presuma bly protective barrier. 
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Dvorak has hypothesized that a relationship exists 
between tumor growth and fibrin cocoon formation (49). If 
this is true, then chemically interfering with the synthesis 
of such a structure should result in an altered tumor growth. 
From this investigation, it is apparent that such a relation-
ship exists although the precise nature of this relationship 
is not clear. However, the presence or the absence of 
fibrin was not demonstrated in the present study. 
Although weight differences between the tumors of 
the two groups was the primary focus of this research, less 
objective criteria such as degree of inflammation, over-
lying skin adhesion (attachment) and host immune response 
were also evaluated. For these parameters, differences 
between the two groups were not large enough to be sig-
• 
nificant. Of interest was the fact that, in the experi-
mental group viable tumor cells were limited to the zonal 
area at the surface of the tumor. This can perhaps be ex-
plained by the fact that oxygen and nutrients can diffuse 
into this zone to keep the tumor cells alive. 
In 1972, Elias and Bruganolas reported the bene-
ficial effect of anticoagulation in four patients with meta-
static carcinoma of the lung not responding to the multiple 
chemotherapeutic agents alone. After the addition of heparin, 
excellent clinical responses were seen and confirmed (65). 
In 1975, Elias, Shukla, and Mink again reported a favorable 
experience using heparin in patients with metastatic 
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carcinoma of the lung (63). Fourteen patients not re-
sponding to multiple conventional chemotherapy andjor radio-
therapy showed significant responses to the same chemo-
therapeutic agent andjor radiotherapy after heparinization 
(52, 63). 
However, Rohwedder and Sagastume (64) have reported 
no significant beneficial effect after the addition of hep-
arin to anti-cancer therapy in patients with metastatic 
carcinoma of the lung. 
All of the studies cited above tested heparin in 
solid tumors . In 1978, Drapkin et al. reported on nine 
patients with acute promyelocytic leukemia who showed favor-
able responses to heparin therapy (88). More recently, 
Zacharski et al. (60) reported on 25 patients with small 
cell carcinoma of the lung receiving warfarin in addition 
to conventional cancer therapy. Median survival in the 
treatment group was twice as long as in the control or non-
anticoagulated group. 
The majority of the clinical studies cited above 
support the hypothesis of this research project that anti -




Fifty-four of the inbred strain c3HjHeJ Jackson 
Laboratory female mice approximately one year old and 
weighing 20- 26 grams were implanted with spontaneously 
occurring mouse mammary tumors and equally divided into 
control and experimental groups. The experimental group 
received 4.0 mgjkg sodium heparin (128 Ujmg) intraperito-
neally on a twelve-hour schedule . Effective anticoagula-
tion was demonstrated by a prolongation of clotting time . 
Animals (C 3HjHeJ mice) were sacrificed at varying inter-
vals up to 8 days, tumors retrieved and weighed . Definite 
retardation of tumor growth was demonstrated in the experi-
mental group. 
The following conclusions appear justifie d: 
(i) Heparin at the dosage and route used here 
is an effective anticoagulant agent . 
(ii) No major hemorrhagic accidents were seen 
in the anticoagulated mice at the dos e 
used. 
(iii) Implant e d mouse mammary tumor growth was 
inhibite d by heparin . 
(iv) Polymorphonuclear, macrophage , T lympho cy t e 
and tumor cell necrosis appeared to b e too 
$9 
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variable for specific conclusions to be 
drawn. 
(v) Overlying skin attachment (adhesion), blood 
vessel congestion (dilation) and the presence 
of local edema appeared more pronounced and 
occurred more frequently in the control 
group. 
The author agrees with Zacharski (60) that antico-
agulant therapy may have an important role to play in the 
treatment of solid tumors such as mouse mammary adeno-
carcinoma. Further investigation will be necessary to con-
firm these findings and to confirm that the beneficial ef-
fect of heparin is exclusively due to its antithrombin 
activity. Experiments utilizing a pharmacologically dif-
ferent anticoagulant (e.g. warfarin) would be especially 
meaningful . 
The present study limited heparin treatment t o a 
maximum term of 8 days. It would be useful to study 
the effect of heparin for much longer periods. End points 
for such long term experiments could be animal death o r 
the complete disappearance of the implanted tumor mass. 
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